多发性 myeloma XI 试验中配对肿瘤样本的拷贝数演变与患者结局分析
该研究对 178 对来自 NCRI Myeloma XI 试验的配对诊断-复发肿瘤样本进行数字多重连接依赖探针扩增分析,发现拷贝数畸变(CNA)的获得在 MM 亚型间模式不同,分支演化模式与较差总生存显著相关(HR 2.61,P=0.0048),复发时获得 gain(1q) 独立关联较短 OS(HR=2.00,P=0.021)。
要点
- 复发时 CNA 获得模式因 MM 亚型而异:HRD 以分支演化为主,t(4;14) 呈线性,t(11;14) 稳定。
- 分支演化模式显著关联较差 OS(HR 2.61,P=0.0048)。
- 复发时获得 gain(1q) 独立关联较短 OS(HR 2.00,P=0.021)。
核心结论
- 复发时 CNA 获得模式因 MM 亚型而异,分支演化及获得 gain(1q) 与较差 OS 相关。
- 重复分子谱分析有助于刻画疾病演化并指导复发管理。
研究设计与样本
- 对 178 对来自 NCRI Myeloma XI 试验患者的诊断-复发配对肿瘤样本进行数字多重连接依赖探针扩增分析。
主要发现
- HRD 肿瘤以分支模式演化,t(4;14) 呈线性模式,t(11;14) 呈稳定模式。
- CCND2 肿瘤较 CCND1 肿瘤复发时获得 del(17p) 明显富集。
- 获得性 CNA 不受大剂量美法仑或来那度胺维持随机化影响。
- 分支演化模式显著关联较差 OS(HR 2.61,P=0.0048)。
- 复发时获得 gain(1q) 独立关联较短 OS(HR=2.00,P=0.021)。
临床怎么用
- 可考虑对复发 MM 患者重复分子谱分析以识别高危演化模式如分支演化或获得 gain(1q)。
- 治疗决策中需关注 CNA 演化特征,合理序贯治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Structural chromosomal changes including copy number aberrations (CNAs) are a major feature of multiple myeloma (MM), however their evolution in context of modern biological therapy is not well characterized. To investigate acquisition of CNAs and their prognostic relevance in context of first-line therapy, we profiled tumor diagnosis-relapse pairs from 178 NCRI Myeloma XI (ISRCTN49407852) trial patients using digital multiplex ligation-dependent probe amplification. CNA profiles acquired at relapse differed substantially between MM subtypes: hyperdiploid (HRD) tumors evolved predominantly in branching pattern vs. linear pattern in t(4;14) vs. stable pattern in t(11;14). CNA acquisition also differed between subtypes based on CCND expression, with a marked enrichment of acquired del(17p) in CCND2 over CCND1 tumors. Acquired CNAs were not influenced by high-dose melphalan or lenalidomide maintenance randomization. A branching evolution pattern was significantly associated with inferior overall survival (OS; hazard ratio (HR) 2.61, P = 0.0048). As an individual lesion, acquisition of gain(1q) at relapse was associated with shorter OS, independent of other risk markers or time of relapse (HR = 2.00; P = 0.021). There is an increasing need for rational therapy sequencing in MM. Our data supports the value of repeat molecular profiling to characterize disease evolution and inform management of MM relapse.
引用
- Croft J, Ellis S, Sherborne AL, et al. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia. 2020. PMID: 33262523. doi:10.1038/s41375-020-01096-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。